News – Page 889 – Endpoints News

AbbVie, Scripps expand partnership, fortify focus on cancer drugs

6 years ago

Paul Hudson promises a bright new future at Sanofi, kicking loose me-too drugs and focusing on landmark advances. But ...

6 years ago

South Korea jails 3 Samsung execs for destroying evidence in BioLogics probe

6 years ago

Cellarity, Flagship's $50M bet on network biology, marries machine learning and single-cell tech for drug discovery

6 years ago

Sanofi’s big week includes a promising PhIII for an orphan disease drug, with plans for a pitch to the FDA

6 years ago

Inscripta pushes funding to $260 million as they launch genome editing platform

6 years ago

Republicans unveil a drug price bill to rival the Democrats — promising lower prices and more cures

6 years ago

Perceptive teams up with Chris Garabedian to open up a new, $210M biotech fund focused on A rounds

6 years ago

US biosimilar launches about to turn a corner

6 years ago

Sanofi CEO Hudson lays out new R&D focus — chopping diabetes, cardio and slashing $2B-plus costs in surgical ...

6 years ago

In a play-by-play of the $9.7B MedCo buyout, Novartis admits it overpaid while offering a huge windfall to execs

6 years ago

Game on: Regeneron's BCMA bispecific makes clinical data debut, kicking off multiple myeloma matchup with ...

6 years ago

Early-stage cancer biotech nails $85M C round; Flemming Ornskov's Galderma scores 'breakthrough' status

6 years ago

FDA lifts hold on Abeona's butterfly disease therapy, paving way for pivotal study

6 years ago

Roche faces another delay in struggle to navigate Spark deal past regulators — but this one is very short

6 years ago

KalVista's diabetic macular edema data falls short — will Merck walk away?

6 years ago

#ASH19: Here’s why Merck is paying $2.7B today to grab ArQule and its next-gen BTK drug, lining up Eli Lilly ...

6 years ago

ObsEva makes case for hormone suppressive therapy in uterine fibroid study, but safety qualms vex investors

6 years ago

New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest, buying Synthorx for $2.5B

6 years ago

Bristol-Myers is making a bee-line to the FDA with positive liso-cel data — but is it too late in the CAR-T game?

6 years ago

Patient #9 has been a concern, but Sangamo and Pfizer are bullish about winning the marathon hemophilia A gene ...

6 years ago

J&J team shows off 'breakthrough' BCMA CAR-T data, and that could cause a big headache at bluebird and Bristol-Myers

6 years ago

J&J fronts $750M cash to grab a failed cancer drug that’s been repurposed as a powerful anti-inflammatory

6 years ago

Jasper Therapeutics launches out of Stanford with new approach to stem cell treatment

6 years ago

First page Previous page 886 887 888889890 891 892 Next page Last page